WILMINGTON, Delaware and LYON, France – Ananda Scientific Inc., a clinical-stage drug development company pursuing innovative therapies for high-impact neuropsychiatric disorders, today announced the signing of a Memorandum of Understanding (MOU) with Benta SAS. The MOU expresses the parties’ intention to explore potential cooperation focused on accelerating the development and future availability of a novel treatment for Post-Traumatic Stress Disorder (PTSD) in Europe and the Middle East/North Africa (MENA) region.
PTSD is a chronic and debilitating condition affecting millions of people worldwide. Despite its significant prevalence and devastating impact on patients, families, and communities, no new medication has been approved for PTSD in over two decades, highlighting a critical unmet medical need.
As part of its clinical development plan, Ananda Scientific is currently advancing Nantheia™ , an investigational medicine being evaluated in clinical trials for the treatment of PTSD. Under the terms of the MOU, Ananda Scientific will continue to lead all aspects of clinical development, while Benta will focus on leveraging its manufacturing expertise and infrastructure to support potential future product development, production expansion, and regional distribution in Europe and the MENA region.
“This MOU represents an important step in our mission to offer innovative therapies for neuropsychiatric disorders where patients have limited treatment options,” said Sohail Zaidi, CEO of Ananda Scientific Inc. “There is an urgent and growing global need for new therapies for PTSD. With our Nantheia™ clinical development program , we are advancing a promising candidate through rigorous clinical evaluation, and potential collaborations like this can help ensure readiness for future manufacturing and distribution.”
“At Benta, we are committed to supporting the advancement of transformative therapies that can have a real impact on patients’ lives,” said Bernard Tannoury, President of Benta SAS (France). “We are pleased to explore opportunities to contribute our production capacity and technical expertise to support Ananda Scientific’s efforts in bringing innovative PTSD treatments to patients in Europe and the MENA region.”
This MOU highlights the shared interest of both companies in promoting mental health treatment through scientific innovation and the development of high-quality pharmaceuticals, aiming to improve outcomes for patients affected by PTSD.
About Ananda Scientific Inc, USA
Ananda Scientific Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders. The company’s flagship research program, Nantheia™ , is currently being evaluated in clinical trials for Post-Traumatic Stress Disorder (PTSD) and other neuropsychiatric indications. By leveraging advanced drug delivery technology and a robust clinical research pipeline, Ananda is committed to addressing key unmet medical needs through rigorous clinical research and international partnerships.
About Benta SAS, France
Benta SAS is a pharmaceutical company based in France, dedicated to the development, manufacture and distribution of high-quality pharmaceutical products. The company maintains partnerships with leading innovators worldwide in order to promote cutting-edge therapies and improve access to innovative treatments in various therapeutic areas, with a growing focus on Europe and the MENA region.
The original language text of this announcement is the official, authorized version. Translations are provided for convenience only and should be referred to the original language text, which is the only legally binding version.
Contacts
Media contact:
Christopher BG Moore,
Senior Vice President of Corporate Affairs,
Ananda Scientific Inc.
Email:media@anandascientific.com
Stephanie Sabra, Communications Manager – Press Inquiries
Benta SAS
Email:communication@benta-group.com
Rana Kateb, Legal Advisor – Legal or Transactional Consultations
Benta SAS
Email:rana.kateb@benta-group.com
Source : Businesswire
Get the latest news and insights that are shaping the world. Subscribe to Impact Newswire to stay informed and be part of the global conversation.
Got a story to share? Pitch it to us at info@impactnews-wire.com and reach the right audience worldwide!
Discover more from Impact Newswire
Subscribe to get the latest posts sent to your email.
